New approval paths needed: report

Share this article:

The Pew Charitable Trusts, Biotechnology Industry Organization (BIO), GlaxoSmithKline, and Pharmaceutical Research and Manufacturers of America (PhRMA) are voicing basic support for FDA's efforts to develop an alternative approval pathway for certain drugs intended to address unmet medical needs.

In comments to FDA, Pew reported results from a Jan. 31 meeting among stakeholders that explored the feasibility of such an alternate approval pathway. All panelists agreed on the urgent need for new antibiotics. The Pew report says that questions remaining from a business perspective include how “unmet need” would be defined and what evidence would be required for agency approval.

PhRMA says it is ready to continue to work with FDA and other stakeholders toward establishing an appropriate and targeted regulatory approach, but adds that FDA should first turn its attention to issuing science-based guidance related to clinical trials for antibiotics and the pathogen-focused development of antibiotics.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters